Status:
COMPLETED
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients
Lead Sponsor:
Endeavor Health
Conditions:
Residual Neuromuscular Blockade
Eligibility:
All Genders
18-80 years
Brief Summary
The majority of patients undergoing surgery receive neuromuscular blocking agents (NMBAs) in the operating room. Reversal of neuromuscular blockade at the conclusion of a general anesthetic is accompl...
Detailed Description
Patients undergoing thoracic surgical procedures receive a general anesthetic in the operating room. As part of this general anesthetic, patients are administered a neuromuscular blocking agent (NMBA ...
Eligibility Criteria
Inclusion
- ASA I to III patients 18-80 years of age, presenting for surgery requiring maintenance of neuromuscular blockade in the operating room, will be eligible for enrollment.
Exclusion
- Exclusion criteria include: 1) presence of an underlying neuromuscular disease 2) use of drugs known to interfere with neuromuscular transmission (antiseizure medications, anticholinesterases, magnesium sulfate) or 3) renal insufficiency (serum creatinine \> 1.8 mg/dL) or renal failure.
Key Trial Info
Start Date :
February 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01837498
Start Date
February 1 2014
End Date
March 1 2017
Last Update
February 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NorthShore University HealthSystem
Evanston, Illinois, United States, 60201